The Third International Inflammatory Breast Cancer Conference

Breast Cancer Research

Volumn 15, Issue 6, 2013, Pages

  van Golen, Kenneth L ^a,b   Cristofanilli, Massimo ^c  

^a UNIVERSITY OF DELAWARE   (United States)

^b HELEN F GRAHAM CANCER CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; AZD 8931; AZD 8931T; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BODY MASS; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL RESEARCH; ECHOMAMMOGRAPHY; EDUCATIONAL STATUS; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FAMILY HISTORY; GENE EXPRESSION; HUMAN; INFLAMMATORY BREAST CANCER; MAMMOGRAPHY; MASTECTOMY; MOUSE MAMMARY TUMOR ONCOVIRUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICIAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; UNITED STATES; FEMALE; GENETICS; INFLAMMATORY BREAST NEOPLASMS; MEDICAL RESEARCH; METABOLISM; MOLECULARLY TARGETED THERAPY; VIROLOGY;

BIOMEDICAL RESEARCH; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MOLECULAR TARGETED THERAPY;

EID: 84887530130     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3571     Document Type: Article

References (17)

1. Dushkin H, Cristofanilli M. Inflammatory breast cancer. J Natl Compr Canc Netw 2011, 9:233-240.
2. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, Lucci A, Ueno NT, Cristofanilli M. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 2010, 60:351-375. 10.3322/caac.20082, 20959401.
3. Dang CV. MYC on the path to cancer. Cell 2012, 149:22-35. 10.1016/j.cell.2012.03.003, 3345192, 22464321.
4. Duke TJ, Jahed NC, Veneroso CC, Da Roza R, Johnson O, Hoffman D, Barsky SH, Levine PH. A cluster of inflammatory breast cancer (IBC) in an office setting: additional evidence of the importance of environmental factors in IBC etiology. Oncol Rep 2010, 24:1277-1284.
5. Schlichting JA, Soliman AS, Schairer C, Schottenfeld D, Merajver SD. Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008. Breast Cancer Res Treat 2012, 134:1257-1268. 10.1007/s10549-012-2133-2, 22733221.
6. Liu H, Kato Y, Erzinger SA, Kiriakova GM, Qian Y, Palmieri D, Steeg PS, Price JE. The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. BMC Cancer 2012, 12:583. 10.1186/1471-2407-12-583, 3526403, 23217186.
7. Fitzgerald DP, Emerson DL, Qian Y, Anwar T, Liewehr DJ, Steinberg SM, Silberman S, Palmieri D, Steeg PS. TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther 2012, 11:1959-1967. 10.1158/1535-7163.MCT-12-0061, 22622283.
8. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res 2009, 15:6639-6648. 10.1158/1078-0432.CCR-09-0951, 2783487, 19825949.
9. Robertson FM, Petricoin, Iii EF, Van Laere SJ, Bertucci F, Chu K, Fernandez SV, Mu Z, Alpaugh K, Pei J, Circo R, Wulfkuhlse J, Ye Z, Boley KM, Liu H, Moraes R, Zhang X, Demaria R, Barsk SH, Sun G, Christofanilli M. Amplification of anaplastic lymphoma kinase (ALK) as a common genetic alteration in inflammatory breast cancer. Springerplus 2013, 2:497. 10.1186/2193-1801-2-497, 3791224, 24102046.
10. Lehman HL, Dashner EJ, Lucey M, Vermeulen P, Dirix L, Van Laere S, van Golen KL. Modeling and characterization of inflammatory breast cancer emboli grown in vitro. Int J Cancer 2013, 132:2283-2294. 10.1002/ijc.27928, 23129218.
11. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML, Harris J, Westlund RE, Salazar V, Zaks TZ, Spector NL. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008, 26:1066-1072. 10.1200/JCO.2007.13.9949, 18212337.
12. Cristofanilli M, Alpaugh KR, Ross J, Binghman C, Wu H, Stephens P, Lipson D, Palmer G. Next generation genomic sequencing (NGS) identifies molecular targets in inflammatory breast cancer (IBC). Cancer Res 2012, 72. abstract PD5-01(124s).
13. Alpaugh RK, Bingham C, Fittipaldi P, Banzi M, Palmber G, Christofanilli M. What is the appropriate sample (s) on which to perform sequencing for mutational analysis to guide the selection of targeted therapy?. Cancer Res 2012, 72. abstract PD5-03(125s).
14. Le-Petross HT, Cristofanilli M, Carkaci S, Krishnamurthy S, Jackson EF, Harrell RK, Reed BJ, Yang WT. MRI features of inflammatory breast cancer. AJR Am J Roentgenol 2011, 197:W769-W776. 10.2214/AJR.10.6157, 21940550.
15. Le-Petross H, Uppendahl L, Stafford J. Sonographic features of inflammatory breast cancer. Semin Roentgenol 2011, 46:275-279. 10.1053/j.ro.2011.04.003, 22035669.
16. Sereni MI, Pierobon M, Angioli R, Petricoin EF, Frederick MJ. Reverse phase protein microarrays and their utility in drug development. Methods Mol Biol 2013, 986:187-214. 10.1007/978-1-62703-311-4_13, 23436414.
17. Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Pavlyuk M, Kraemer S, Bidard FC, Viens P. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 2012, 13:375-384. 10.1016/S1470-2045(12)70049-9, 22377126.